← Leaderboards
Niall Barron
State University Of New York At Buffalo
$327,737
Attributed
$1,310,949
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $452.2K · FY2015–17$500K$375K$250K$125K$0
'15
'16
'17
Funding mix
By agency
NIH$1,310,949 · 1
By mechanism
R01$1,310,949 · 1
Top collaborators
- Wen Wee Ma3 shared
- Chris Scott3 shared
- Robert M Straubinger3 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Wen Wee Ma$737,204
- Robert M Straubinger$4,875,752
- Chris Scott$539,205
- Paras N. Prasad$3,868,715
- Jun Xia$3,270,650
Others in their field
Top investigators on “Disease Progression”
- Lawrence Corey · Fred Hutchinson Cancer Center$405,086,239
- Constance Ann Benson · University Of California, San Diego$244,117,339
- Jeffrey P Krischer · University Of South Florida$225,151,653
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$150,116,206
- Peter B. Gilbert · Fred Hutchinson Cancer Center$146,027,526
Research focus
Disease ProgressionDrug CarriersBloodDiagnosisBaseBlood VesselsCancer BiologyCancer CellAffinityCancer TherapyCetuximabCharacteristicsChemotherapyClinical DataClinically RelevantClinical TrialsCombined Modality TherapyComplexCytotoxicityBlood FlowDensityDepositionDesignDrug Delivery Systems
Grant awards (3)
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2017 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$429,377
R01 · FY2016 · CA
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium$452,195
R01 · FY2015 · CA